United-Guardian Reports Increased Third Quarter Sales & Earnings

Rhea-AI Summary

United-Guardian, Inc. (NASDAQ:UG) announced financial results for Q3 and first nine months of 2023. Q3 sales increased to $3,057,518 from $2,417,022, with net income rising to $626,756 from $345,518. Sales for the nine-month period decreased to $8,278,141 from $9,935,557, while net income decreased to $1,843,931 from $1,890,307. Sales increased in all main product categories, with cosmetic ingredient sales up 42%, pharmaceutical sales up 3%, and medical lubricant sales up 73%. The company plans to implement changes in its marketing strategy in Q1 2024 to increase sales.

Positive

• Sales for Q3 increased by 26% compared to the same period in 2022.
• Cosmetic ingredient sales increased by 42%, pharmaceutical sales increased by 3%, and medical lubricant sales increased by 73%.
• Net income for the nine-month period was slightly behind the same period in 2022.
• Earnings per share for Q3 doubled compared to the same period in 2022.
• The company plans to implement changes in its marketing strategy in Q1 2024 to increase sales.

Negative

• None.

HAUPPAUGE, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and first nine months of 2023. Third quarter sales increased from $2,417,022 to $3,057,518, with net income increasing from $345,518 ($0.07 per share) to $626,756 ($0.14 per share). Sales for the nine-month period ended September 30^th decreased from $9,935,557 in 2022 to $8,278,141 in 2023 due to lower sales in the first half of the year. Net income for the nine-month period decreased from $1,890,307 ($0.41 per share) in 2022 to $1,843,931 ($0.40 per share) in 2023.

Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales increased by 26% for the third quarter of 2023 compared with the same period in 2022. Sales increased in all our main product categories, with cosmetic ingredient sales up 42%, pharmaceutical sales up 3%, and medical lubricant sales up 73%. While overall sales for the first nine months of 2023 decreased slightly compared with the comparable period in 2022, our net income and earnings per share for the first nine months of 2023 were only slightly behind the same period in 2022, and third quarter earnings per share doubled over the same period in 2022. We are in the process of re-evaluating our current marketing strategy, and plan to implement changes in the first quarter of 2024. We anticipate that these changes will enable us to increase sales in all our product categories, especially sales of our cosmetic ingredients in the regions that are underperforming. We are hopeful that these efforts will result in increased sales moving forward.”

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, and medical lubricants.

	Contact:	Donna Vigilante
		(631) 273-0900
		dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Financial Results for the
Three and Nine Months Ended
September 30, 2023 and 2022
STATEMENTS OF INCOME
(unaudited)
		THREE MONTHS ENDED SEPTEMBER 30,					NINE MONTHS ENDED SEPTEMBER 30,
		2023			2022			2023			2022
Net sales	$	3,057,518		$	2,417,022		$	8,278,141		$	9,935,557
Costs and expenses:
Cost of sales		1,749,041			1,076,035			4,272,043			4,479,905
Operating expenses		488,464			532,333			1,580,503			1,699,311
Research and development		98,141			120,924			353,829			364,856
Total costs and expenses		2,335,646			1,729,292			6,206,375			6,544,072
Income from operations		721,872			687,730			2,071,766			3,391,485
Other Income:
Investment income		79,682			46,995			182,264			146,405
Net (loss) gain on marketable securities		(14,357	)		(300,526	)		65,823			(1,154,464	)
Total other income (expense)		65,325			(253,531	)		248,087			(1,008,059	)
Income before provision for income taxes		787,197			434,199			2,319,853			2,383,426
Provision for income taxes		160,441			88,681			475,922			493,119
Net income	$	626,756		$	345,518		$	1,843,931		$	1,890,307
Earnings per common share
(Basic and Diluted)	$	0.14		$	0.07		$	0.40		$	0.41
Weighted average shares – basic
and diluted		4,594,319			4,594,319			4,594,319			4,594,319

Additional financial information can be found on the company’s web site at www.u-g.com.

FAQ

What are the financial results of United-Guardian for Q3 and first nine months of 2023?

In Q3, sales increased to $3,057,518 from $2,417,022, with net income rising to $626,756 from $345,518. For the nine-month period, sales decreased to $8,278,141 from $9,935,557, while net income decreased to $1,843,931 from $1,890,307.

How did sales perform in different product categories?

Sales increased in all main product categories. Cosmetic ingredient sales were up 42%, pharmaceutical sales were up 3%, and medical lubricant sales were up 73%.

What are the plans of United-Guardian to increase sales?

The company plans to implement changes in its marketing strategy in Q1 2024 to increase sales, especially in regions with underperforming cosmetic ingredient sales.